DeepLook Medical – a healthtech company specializing in visual enhancement technology for advanced medical imaging – announced it marked the 11th investment in Xcellerant VC Fund 1. Michael Shufeldt, MBA, Principal at Xcellerant Ventures, will join the board.
DeepLook Medical’s flagship product, DL Precise, is an innovative AI-powered software that equips healthcare professionals with the tools to detect and assess suspicious lesions in dense breast tissue accurately. And by utilizing algorithms and shape-recognition technology DL Precise delivers unmatched precision in visualizing, measuring, and segmenting abnormal growths. And this breakthrough can potentially improve early cancer detection significantly, ultimately enhancing patient outcomes.
DeepLook Medical secured the first close of its Series A round, which will pave the way for ongoing growth and innovation. And the company plans to use this capital to further commercialize its technology with both current and new partners, explore applications in additional modalities, and broaden its global presence.
KEY QUOTES:
“We’re proud to support DeepLook in delivering solutions that empower physicians to make more accurate diagnoses and improve patient care offering a more accurate and efficient method for detecting potential abnormalities. The DL Precise software marks a significant advancement in medical imaging technology, positioning DeepLook Medical at the forefront of innovation. We believe this technology has the potential to redefine how healthcare providers approach breast cancer detection, particularly in cases where clarity and precision are most needed.”
-Michael Shufeldt
